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A B S T R A C T   
Stroke is the 2nd leading cause of death worldwide and the leading cause of physical disability and cognitive 
issues. Although we have made progress in certain aspects of stroke treatment, the consequences remain sub-
stantial and new treatments are needed. Hypertension has long been recognised as a major risk factor for stroke, 
both haemorrhagic and ischaemic. The renin angiotensin system (RAS) plays a key role in blood pressure reg-
ulation and this, plus local expression and signalling of RAS in the brain, both support the potential for targeting 
this axis therapeutically in the setting of stroke. While historically, focus has been on suppressing classical RAS 
signalling through the angiotensin type 1 receptor (AT1R), the identification of a counter-regulatory axis of the 
RAS signalling via the angiotensin type 2 receptor (AT2R) and Mas receptor has renewed interest in targeting the 
RAS. This review describes RAS signalling in the brain and the potential of targeting the Mas receptor and AT2R 
in preclinical models of ischaemic stroke. The animal and experimental models, and the route and timing of 
intervention, are considered from a translational perspective.   
1. Introduction 
Stroke is a leading cause of death and disability worldwide [1], and can 
result in the development of dementia in 30% of cases [2,3], yet treatment 
options for this condition are limited. Stroke can be caused by a ruptured 
cerebral blood vessel, known as haemorrhagic stroke, or more commonly by 
the blockage of a blood vessel within the brain, known as ischaemic stroke 
[4]. Starvation of the brain tissue of oxygen and glucose during ischaemia 
results in a pathophysiological cascade of damage consisting of ionic dys-
regulation, excitotoxicity, oxidative stress and inflammation [5]. Re-
canalization of the vessel, either pharmacologically using a clot busting drug 
known as tissue plasminogen activator (tPA) or by mechanical clot removal 
known as thrombectomy remain the only available clinical interventions. 
Different aspects of stroke pathophysiology have been previously targeted 
as neuroprotective strategies [6], but so far, aside from improvements 
achieved utilising thrombectomy [7–9] there has been no progress towards 
improving patient outcome following ischaemic stroke. It is recognised that 
reperfusion paradoxically results in further injury by reperfusion injury [10] 
but the benefit achieved through recanalization outweighs the cost asso-
ciated with failure to restore blood flow. There is an ongoing quest to de-
velop neuroprotective strategies to increase tissue salvage and improve 
functional outcome for patients post stroke and the hope is that the efforts of 
the preclinical stroke community to improve methodological rigor in ex-
perimental stroke research [11–13] will bring a novel neuroprotectant to 
fruition. 
The renin angiotensin system (RAS) is a physiological system that 
maintains cardiovascular homeostasis through maintenance of arterial 
blood pressure (BP). Classical RAS signalling mediated by Angiotensin 
II (Ang II) via the Angiotensin II type 1 receptor (AT1R) increases sys-
temic BP; however it also has further effects on a tissue level that are 
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implicated in disease [14–16]. Hypertension is the key modifiable risk 
factor for stroke [17], systemic RAS blockade, with ACE inhibitors 
(ACEi) or Ang II type 1 receptor (AT1R) antagonists (angiotensin re-
ceptor blockers; ARBs), is a common therapy for treating hypertension 
[18] and with efficient BP control the risk of stroke is reduced [19,20]. 
However, the benefits of modulation of BP acutely post-stroke remains 
controversial [21]. Evidence of the existence of local expression and 
signalling of RAS within the brain may provide a potential therapeutic 
target for neurological or cerebrovascular disorders including ischaemic 
stroke, although whether this will be independent of BP modulation 
will be dependent on many factors including dose and route of delivery. 
This review will outline RAS receptor signalling and summarise the 
current available evidence for the potential benefit of counter-reg-
ulatory RAS receptor agonism in ischaemic stroke. 
2. The Renin Angiotensin System 
In the classical systemic RAS, the biologically active peptide, Ang II, is 
produced through the actions of the enzymes renin and angiotensin con-
verting enzyme (ACE) and exerts its effects primarily through the AT1R 
causing increased BP via vasoconstriction, increased water and sodium 
uptake in the kidney directly and via aldosterone and vasopressin release, 
and stimulation of the thirst response. (Fig. 1 and associated references). 
A counter-regulatory axis of this system exists [30], consisting of an 
alternative enzyme, ACE2, which produces the peptides, Ang-(1–9) and 
Ang-(1–7), and alternative receptors for these to act through, the Ang II 
type 2 receptor (AT2R) and Mas receptor respectively. This produces 
antagonistic effects to AT1R signalling. This is a simplistic summary of 
the RAS and counter-regulatory RAS but realistically the system is 
much more complex consisting of various other enzymes, peptides and 
receptors as outlined in Fig. 2. 
3. The RAS in the brain 
The existence of RAS signalling in the brain has long been known; in-
deed early research on Ang II and Ang-(1–7) implied direct actions in the 
brain [55–57]. The central/brain RAS plays a role in the control of systemic 
BP mediated by sympathetic innervation [58], vasopressin release [59] and 
increased thirst [60], and inhibition of the central RAS, by in-
tracerebroventricular injection of the prototype ARB saralasin, has been 
shown to reduce hypertension [61]. Although the majority of RAS research 
focusses on Ang II, it has been shown that conversion of Ang II to Ang III in 
the brain is responsible for the pressor response, where Ang II was in-
effective when its conversion to Ang II was blocked with an aminopeptidase 
A (APA) inhibitor (Fig. 2), and thus Ang III may be the active peptide of 
classical RAS signalling in the central RAS [62]. Indeed, APA inhibitors are 
in clinical development for the treatment of hypertension (reviewed in 
[63]). In the brain, angiotensin immunoreactive nerve fibers have been 
mapped to demonstrate that they originate in circumventricular organs 
(CVO) (such as the subfornical organ, organum vasculosum of the lamina 
terminalis and area postrema). The CVO are areas of the brain which have 
no blood brain barrier (BBB) and therefore can directly interact with the 
circulation and circulating RAS peptides. The angiotensinergic neurons 
project to the paraventricular nucleus, supraoptic nucleus and the nucleus of 
the solitary tract [64,65] which are all neural circuits involved in fluid 
regulation, vasopressin release, sympathetic innervation and thirst response 
[66]. 
Furthermore, expression of the RAS components has been demonstrated 
within the brain, with renin activity demonstrated in the brain independent 
of circulating renin [67], angiotensinogen mRNA detected across the rat 
brain [68] and in both astrocytes [69] and neurons [70], ACE detected by 
radioligand binding in various regions of the human brain [71], and de-
tection of Ang II and other angiotensin peptides (including Ang-(1–9) and 
Ang-(1–7)) in rat and sheep brains [72]. Following the discovery of ACE2, 
its expression was also confirmed within the brain at both a mRNA and 
protein level [73], and expression of the RAS receptors, AT1R, AT2R and 
Mas receptor, in the brain have been demonstrated by numerous studies 
[74–83]. Recently, however, the existence of a locally expressed brain RAS 
has been questioned when van Thiel et al. demonstrated that, despite an-
giotensinogen mRNA expression in mouse brains, angiotensinogen protein 
was not detected, and perfusion of brains before analysis resulted in a 
marked reduction in renin activity, suggesting that the detected renin in 
brain tissues may just be circulating renin trapped within blood vessels in 
the tissues [84]. In contrast, using a newly developed microanalytical assay, 
coupling a laboratory-built capillary electrophoresis nano-electrospray io-
nization platform to a high-resolution mass spectrometer, several of the Ang 
peptides, including Ang I, Ang II, Ang-(1–7) and Ang-(1–9), were detected in 
the subfornical organ and the paraventricular nucleus of the hypothalamus 
in mice [85]. 
4. RAS receptor signalling 
4.1. AT1R 
The AT1R is a G-protein coupled receptor (GPCR) expressed 
throughout tissues of the body. In humans, a single gene exists for the 
Fig. 1. The classical renin angiotensin system. The protein angiotensinogen 
is constitutively released from the liver into the circulation [22]. In response to 
detection of reduced BP, reduced electrolytes or sympathetic innervation in the 
kidney [23], the enzyme renin is secreted from the kidney (red) which cleaves 
angiotensinogen to the decapeptide angiotensin I (Ang I). Angiotensin con-
verting enzyme (ACE) is present on the endothelial wall of blood vessels in 
particular in the lung [24,25]. ACE cleaves Ang I to the octapeptide Ang II, 
which acts upon the angiotensin II type 1 receptor (AT1R) to increase BP and 
blood volume by vasoconstriction of blood vessel [26], stimulating aldosterone 
release from the adrenal gland (on top of the kidney) and hence increasing 
sodium and water uptake [27], and actions on the brain increasing arterial 
pressure by sympathetic innervation or to increase the thirst response and re-
lease vasopressin to increase water uptake [28,29]. ACE inhibitors (ACEi) or 
angiotensin receptor blockers (ARB) (orange) are BP lowering medications 
which block these elements of the RAS to prevent increased BP. Letters in 
peptides indicate the amino acid sequence. (For interpretation of the references 
to colour in this figure legend, the reader is referred to the web version of this 
article.) 
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receptor, however in rodents two pharmacologically indistinguishable 
isoforms exist, AT1AR and AT1BR [86]. The tissue expression of these 
isoforms varies, with AT1AR being the predominant isoform in all tis-
sues, including brain, vasculature, lung and liver, except the adrenal 
and pituitary gland where AT1BR is the predominant isoform [87]. 
AT1R is regulated at a transcriptional level by being downregulated by 
Ang II [88] and can also be modified by numerous other factors such as 
insulin, glucose, estrogen, chemokines, nitric oxide (NO), reactive 
oxygen species (ROS) or low-density lipoprotein (LDL) cholesterol [89] 
with insulin, for example, increasing AT1R expression in vascular 
smooth muscle cells [90] and estrogen [91] and NO [92] leading to a 
down-regulation of AT1R in the hypothalmus or in neurons respec-
tively. AT1R is also regulated by desensitisation to further activation by 
being rapidly internalised [93] or phosphorylated [94,95] upon acti-
vation, or, as is a common feature of GPCR signalling [96], AT1R can 
also be regulated by the formation of heterodimers with other receptors 
such as the bradykinin receptor (B2R) [97], the β-adrenergic receptor 
[98], the Mas receptor [51] or the AT2R [52]. 
Downstream signalling from Ang II at the AT1R involves activation 
of phospholipase C (PLC), phospholipase D (PLD) and phospholipase A2 
(PLA2) along with activation of mitogen-activated protein kinases 
(MAPKs) and NADPH oxidases (NOXs), non-receptor tyrosine kinases 
(NRTKs) or receptor tyrosine kinases (RTKs) (Fig. 3 and associated re-
ferences). In the systemic circulation, these signalling events result in 
contraction of vascular smooth muscle cells but also reactive oxygen 
species (ROS) production, inflammation, apoptosis, proliferation, pro-
tein synthesis, cell growth and migration influencing cell survival and 
pathological effects such as hypertrophy and fibrosis [16,99]. Indeed, 
much of the research on downstream signalling from AT1R has been 
conducted in vascular or cardiac cells, however Ang II mediated effects 
in the brain have also been attributed to some of these signalling 
pathways. For example, AT1R stimulation with Ang II in neuronal 
cultures results in activation of MAPKs [100] while AT1R blockade 
results in the reduction of MAPK activation, with MAPK activation 
being associated with microglial or astrocyte activation [101]. Within 
the brain, classical RAS signalling through AT1R leads to: vasopressin 
release [59] and suppression of the baroreflex, which has been shown 
to be mediated via PLC activation [102]; a switch towards the proin-
flammatory microglia phenotype with increased levels of proin-
flammatory cytokines such as tissue necrosis factor α (TNFα) or inter-
leukin-1β (IL-1β) [103]; increased astrogliosis [104]; or in neurons, 
increased mitochondria-dependent apoptosis [105], increased produc-
tion of ROS leading to apoptosis [106,107] or autophagy activation 
contributing to Ang II induced apoptosis via the AT1R [108]. Ang II 
induces ROS production in neurons via NOX activation which has been 
demonstrated to be mediated by protein kinase C (PKC) [109], but 
neuronal NO synthase (nNOS) is also upregulated by Ang II stimulation 
of neurons, contributing to oxidative stress and subsequent apoptosis 
induction [107]. PKC mediated activation of NOX leading to ROS 
production also results in microglial activation via activation of Rho- 
kinase by NFκB which additionally feeds back to further upregulate 
AT1R expression [110,111]. There is also evidence to suggest that Ang 
II stimulation of AT1R inhibits iron uptake in neurons [112,113] and 
iron metabolism dysregulation is linked to neurodegeneration [114]. 
4.2. Mas receptor 
The Mas receptor is a GPCR coded for by a gene originally identified 
as a proto-oncogene [124] but suggested early to code for an angio-
tensin receptor [125]. Like AT1R and other GPCRs, upon activation by 
Ang-(1–7), the Mas receptor is internalised and therefore desensitised to 
further activation [126]. Additionally, the Mas receptor can form het-
erodimers with other GPCRs, for example with AT2R which is necessary 
for signalling in some cell types [53], or with AT1R causing an in-
hibitory, regulatory effect on AT1R [51]. Ang-(1–7) is the heptapeptide 
product of ACE2 cleavage of Ang II or of ACE cleavage of Ang-(1–9) 
[34,39] (Fig. 2), which shows counter-regulatory effects to AT1R sig-
nalling [46] and mediates its effects through the Mas receptor [127]; 
although there have also been reports of effects mediated via the AT2R 
[128]. AVE 0991 is a nonpeptide, commercially available agonist at the 
Mas receptor, originally characterised in endothelial cells [129] while 
conversely, A779 acts as an antagonist of the Mas receptor [130]. 
Downstream signalling following Mas receptor activation by Ang- 
(1–7) includes activation of the phosphoinositide-3-kinase (PI3K) sig-
nalling pathway and endothelial NO synthase (eNOS) activation along 
with activation of tyrosine phosphatases, PLA2, protein kinase A (PKA) 
Fig. 2. The extended RAS and counter-regulatory axis. Diagram illustrating the 
additional discoveries in the RAS. Prorenin is constitutively secreted from the 
kidney (black block arrow) while cleaved renin is secreted in response to sti-
muli (red block arrow) [31]. Renin acts directly on angiotensinogen to cleave it 
to Ang I, while both prorenin and renin can bind to the (pro)renin receptor 
(PRR) allowing increased cleavage activity of angiotensinogen [32]. The classic 
and counter-regulatory enzymes for angiotensin peptide cleavage, angiotensin 
converting enzyme (ACE) (grey) [33] and ACE2 (green) [34] are shown along 
with additional enzymes which result in peptide cleavage (black) [35–44]. 
Dashed lines represent cleavage while coloured arrows indicate action of the 
peptide upon the colour coded receptors. Ang-(1–5), Ang III, Ang IV, Ang-(1–7) 
and Ang-(1–9) are all active peptides in the RAS [45–49]. Ang A shows a re-
duced vasoconstrictive effect through AT1R compared to Ang II and also acts 
upon the AT2R [50]. The angiotensin II type 2 receptor (AT2R), Mas receptor 
and Mas related GPCR type D (MrgD) receptor form the counter-regulatory axis 
of the RAS, opposing the signalling effects of AT1R [30]. Furthermore, AT1R 
and Mas [51], AT1R and AT2R [52], and AT2R and Mas [53] have been found to 
form signalling heterodimers. AT4R is not a GPCR like the other angiotensin 
receptors, but an enzyme, insulin-regulated membrane aminopeptidase (IRAP) 
[54]. Abbreviations: NEP, neprilysin; TOP, thimet oligopeptidase; PEP, prolyl- 
endopeptidases; MEP, metalloendopeptidases; APA, aminopeptidase A; APN, 
aminopeptidase N; DC, decarboxylase enzyme. Letters in peptides indicate the 
amino acid sequence. (For interpretation of the references to colour in this 
figure legend, the reader is referred to the web version of this article.) 
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or MAPKs (Fig. 4 and associated references). The production of NO and 
arachidonic acid (AA) metabolites causes vasodilation in opposition to 
Ang II AT1R mediated vasoconstriction [127,131,132], while inhibition 
of MAPKs or Src attenuates remodelling in heart [133–135] or vascu-
lature [136]. Conversely, however, the activation of MAPKs, such as 
ERK1/2 or p38 MAPK, by Mas receptor activation has been implicated 
in vasodilation and angiogenesis [137]. 
Specifically in the brain, Ang-(1–7)/Mas has been shown to mod-
ulate central cardiovascular regulation with a BP and heart rate low-
ering effect when Ang-(1–7) was injected into the nucleus of the solitary 
tract (NTS) region within the dorsal medulla of rats [57]. This hypo-
tensive effect is mediated by NO production [138,139], or more spe-
cifically the bradykinin dependent NO pathway of Mas signalling sti-
mulating cyclic GMP (cGMP) and cGMP-dependent protein kinase 
(PKG), resulting in reduced norepinephrine release and reduced sym-
pathetic innervation [140]. Conversely, however, central Ang-(1–7) 
administration into the ventrolateral medulla (VLM) of rats, either the 
rostral VLM (RVLM) [141–143] or the caudal pressor area (CPA) of the 
VLM [141,143], or the RVLM, but not caudal VLM, of rabbits [144] 
resulted in an increase in BP. Additionally, Ang-(1–7) can induce va-
sopressin release, although this may not be mediated by the Mas re-
ceptor [145]. It has also been suggested that Ang-(1–7)/Mas signalling 
in astrocytes rather than neurons may play an important role in car-
diovascular regulation [146]. Taken together, these studies may 
indicate divergent effects of Ang-(1–7) depending on the brain region or 
angiotensin receptor expression in that area. 
Aside from cardiovascular regulation however, Ang-(1–7) and Mas 
receptor signalling have demonstrated specific effects on brain cells 
such as: reduced nuclear and mitochondrial superoxide production 
[147]; improved neuronal survival and reduced oxidative stress in the 
brain mediated via PKA [148], or improved survival and reduced levels 
of ROS in rotenone induced injury of cultured neurons mediated by 
increased antioxidant activity and reduced NOX activity [149]; reduced 
microglial activation and astrogliosis allowing for improved neuronal 
density following traumatic brain injury [150]; reduced inflammation 
in astrocytes mediated by the MAPK inhibition signalling pathway 
[151]; reduced Shiga toxin 2 (Stx2) induced neuronal, astrocyte and 
oligodendrocyte damage [152]; or a switch to the anti-inflammatory 
M2 microglia phenotype with a reduction in pro-inflammatory cyto-
kines (TNFα and IL1β) and increased levels of anti-inflammatory IL-10 
[153]. Moreover, central Ang-(1–7) administration has demonstrated 
an increase in bradykinin levels and expression of bradykinin receptors 
[154] which may itself have neuroprotective effects [155]; or protec-
tion against cerebral endothelial cell dysfunction and oxidative stress 
via NOX inhibition and the PI3K/NO signalling pathway [156]. Ad-
ditionally, Mas receptor signalling pathways (Fig. 4) have been de-
monstrated specifically in neurons with increased NO, AA release, 
MAPK activation and protein kinase B (PKB/Akt) activation with Ang- 
Fig. 3. AT1R signalling. Diagram depicting summary of intracellular 
signalling cascades induced by angiotensin II type 1 receptor (AT1R) 
activation by Ang II, or blocked by angiotensin receptor blockers 
(ARBs) or heterodimerisation with angiotensin II type 2 receptor 
(AT2R) or Mas receptor. Arrows indicate activation while dashed line 
arrows indicate production or cleavage to form a product. Signalling 
information obtained from [16,51,121–123,52,107,115–120]. Ab-
breviations: AA mets, arachidonic acid metabolites; AA, arachidonic 
acid; ASK1, apoptosis signal regulating kinase 1; DAG, diacylglycerol; 
ERK 1/2, extracellular signal related kinase 1/2; FAK, focal adhesion 
kinase; IP3, inositol trisphosphate; JAK, Janus kinase; JNK, c-Jun N- 
terminal kinase; MAPKs, mitogen activated protein kinases; NOX, NAD 
(P)H oxidases; nNOS; neuronal nitric oxide synthacse; NRTKs, non- 
receptor tyrosine kinases; p38, p38 MAPK; PA, phosphatidic acid; PC, 
phosphatidylcholine; PDGFR, platelet derived growth factor receptor; 
PIP2, phosphatidylinositol 4,5-bisphosphate; PKC, protein kinase C; 
PLA2, phospholipase A2; PLC, phospholipase C; PLD, phospholipase D; 
ROS, reactive oxygen species; RTKs, receptor tyrosine kinases. 
Fig. 4. Mas receptor signalling. Diagram depicting summary of in-
tracellular signalling cascades induced by Mas receptor (Mas receptor) 
activation. Agonists and antagonists are also shown along with re-
ceptors with which functional heterodimerisation can occur (AT2R and 
the bradykinin 2 receptor (B2R)). Arrows indicate activation while 
dashed line arrows indicate production or cleavage to form a product. 
Signalling information obtained from [127,131,166,167,132–134, 
137,140,156,164,165]. Abbreviations: AA mets, arachidonic acid me-
tabolites; AA, arachidonic acid; Akt, protein kinase B; cGMP, cyclic 
guanidine monophosphate; eNOS, endothelial nitric oxide synthase; 
MAPKs, mitogen activated protein kinases; NO, nitric oxide; PI3K, 
phosphoinositide-3-kinase; PIP2, phosphatidylinositol 4,5-bispho-
sphate; PIP3, phosphatidylinositol 3,4,5-trisphosphate; PKA: protein 
kinase A; PLA2, phospholipase A2; SHP-2, SH2 domain-containing 
protein tyrosine phosphatase-2. 
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(1–7) treatment [157], or the downregulation of p38 MAPK and NOX 
coupled with the activation of PI3K and PKB/Akt resulting in increased 
levels of brain derived neurotrophic factor (BDNF), a neuronal survival 
promoting protein [158]. 
Finally, Ang-(1–7)/Mas signalling has also been implicated in 
learning and memory, with Ang-(1–7) increasing long-term potentia-
tion in the hippocampus or amygdala via NO production [159,160], 
improving cognitive function in diabetic rats [161], or ACE2 activation 
improving cognition, coupled with reduced neuronal apoptosis, re-
duced inflammation and increased levels of BDNF, mediated via PI3K, 
in an Alzheimer's disease (AD) model [162]. Moreover Mas activation 
has demonstrated reduced anxiety like behaviour [163]. 
4.3. AT2R 
The AT2R shares 34% homology with AT1R with a similar seven 
transmembrane GPCR structure [168]. Its expression is highest in fetal 
tissues and declines after birth [169] although more recently this con-
cept was challenged with a study showing higher levels of AT2R protein 
in brainstem, liver and kidney in adult rats compared to fetal or neo-
natal rats [170]. The gene coding for AT2R has been mapped to the X 
chromosome [171] and studies in rodents have indicated a higher ex-
pression of AT2R in females compared to males due to upregulation by 
estrogen in the brain and heart [172,173], however, others have re-
cently reported no overall sex related differences in AT2R, or AT1R, 
expression in the mouse brain [82]. Other regulators of AT2R expres-
sion include glucocorticoids and cytokines [174] or specifically, the 
nuclear protein poly(ADP-ribose) polymerase-1 (PARP1) [175] or 
transcription factor promyelocytic zinc finger protein (PLZF) [176] 
which regulate AT2R transcription. Further, the AT2R binding protein 
(ATBP)/AT2R interacting protein (ATIP) interacts with the C terminus 
of the receptor to promote its expression on the cell membrane 
[177,178]. Various other angiotensin peptides are reported to be li-
gands at the AT2R, namely Ang III, Ang IV, Ang-(1–7) and Ang-(1–9), 
although the affinity for Ang II is the highest [47,179]. Additionally, 
peptide (CGP42112 [180], β-Pro [7] Ang III [181]) and non-peptide 
(Compound 21, C21 [182]) agonists of AT2R have been developed 
which have further aided the understanding of AT2R signalling. 
Unlike the AT1R and other GPCRs, the AT2R does not display in-
ternalization and desensitisation in response to ligand binding [183] 
and can therefore induce long term signalling effects. However, similar 
to other GPCRs, AT2R can form functional heterodimers for example 
with Mas receptor [53] or the B2R [184], and acts as an antagonist of 
AT1R by forming a heterodimer with this receptor independent of AT2R 
signalling [52]. In addition, AT2R forms homodimers causing con-
stitutive activation without Ang II stimulation [185]. 
AT2R signalling is mediated through activation of protein phos-
phatases, or, similar to Mas receptor signalling, regulation of NO-cGMP, 
and activation of PLA2 leading to systemic effects opposing AT1R sig-
nalling such as vasodilation or anti-fibrotic or anti-hypertrophic effects 
[30] (Fig. 5 and associated references). Additionally, however, inhibi-
tion of MAPK activation due to phosphatase activity via AT2R signalling 
can result in apoptosis induction and this has been demonstrated in 
neuronal cells [186,187]. The induction of apoptosis by AT2R signalling 
occurs in tumor cells, thus implicating this receptor in possible cancer 
treatments [188,189], and also in Chinese hamster ovary and vascular 
smooth muscle cells [190]. In primary neuronal cultures, AT2R con-
tributed to apoptosis induction only when in combination with other 
insults such as zinc treatment [191] or ultraviolet light exposure [187] 
suggesting additional complexities to AT2R signalling depending on the 
environment. Conversely, cell death was reduced in vitro in neurons 
subjected to glucose deprivation treated with the AT2R agonist, 
CGP42112 but not C21 [192]. Interestingly, however, in vivo delivery of 
CGP42112 (ip) [192] or C21 (daily ip injections) [193] resulted in re-
duced numbers of apoptotic neurons after experimental stroke in mice. 
Combined, these studies demonstrate AT2R stimulation may exert a 
beneficial effect through both apoptotic and anti-apoptotic mechan-
isms, perhaps dependent on the cell type affected or timing in terms of 
the balance between neuro-injury and neurorepair. 
Other effects of AT2R signalling in the brain are reduced ROS pro-
duction [194], improved neuronal cell survival [195,196], a switch to 
the anti-inflammatory M2 microglia phenotype [110], and a reduction 
in the pro-inflammatory cytokine, TNFα, and increased levels of anti- 
inflammatory IL-10 [197,198]. Moreover, AT2R signalling in brain cells 
has been shown to directly oppose AT1R signalling; for example redu-
cing Ang II induced NOX activity and subsequent ROS production in 
neuronal cultures [199], or activation of protein phosphatase 2A 
(PP2A) causing inhibition of PKC and the subsequent NOX activation 
and ROS production which would cause microglial activation [110]. In 
addition, the phosphatase mediated inhibition of MAPK signalling 
pathway of AT2R, namely PP2A inhibition of ERK1/2 activity, has been 
confirmed in neuronal cultures [100,200]. Interestingly, AT2R stimu-
lation also modulates vasopressin release in the brain via synapse in-
teraction of AT2R positive neurons with vasopressin secreting neurons, 
counteracting Ang II induced vasopressin release by AT1R [201]. 
Further effects of AT2R signalling in neurons include the modulation 
of neuronal excitability, through reduction of T-type calcium channel 
currents via phosphotyrosine phosphatase activity [202,203]. or in-
creased potassium channel currents via PLA2, PP2A activation or NO 
production [204–206]; induction of neurite outgrowth and differ-
entiation via NO production [207–210] which may be via the PI3K/Akt 
pathway [211] or increased MAPK (ERK1/2) activity [209,212,213]; 
increased neuronal migration via PP2A activation [214]; or induction 
of neurogenesis and neural stem cell proliferation via Akt activation, 
ERK activation and modulation of potassium channels [215]. Con-
versely however, other neuronal cell lines have demonstrated reduced 
proliferation with AT2R stimulation [213]. 
The demonstration of local effects of both AT2R and Mas receptor 
signalling in the brain has led to the exploration of targeting the RAS for 
Fig. 5. AT2R signalling. Diagram depicting summary of intracellular signalling 
cascades induced by angiotensin II type 2 receptor (AT2R) activation. Agonists 
and antagonists are also shown along with receptors with which functional 
heterodimerisation or homodimerization can occur. Arrows indicate activation 
while dashed line arrows indicate production or cleavage to form a product. 
Signalling information obtained from [53,100,219,221–227,128,174, 
186,187,203–206]. Abbreviations: AA mets, arachidonic acid metabolites; AA, 
arachidonic acid; Bcl-2, B-cell lymphoma 2; cGMP, cyclic guanidine mono-
phosphate; eNOS, endothelial nitric oxide synthase; JNK; c-Jun N-terminal ki-
nase; MAPKs, mitogen activated protein kinases; MKP-1, MAPK phosphatase-1; 
NO, nitric oxide; PLA2, phospholipase A2; PP2A, protein phosphatase 2A; SHP- 
1, Src homology region 2 domain-containing phosphatase. 
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many neurological disorders, for example Parkinson's disease [216], 
depression [217], Alzheimer's Disease (AD) [218], cognitive impair-
ment [219] or as reviewed here and elsewhere, the cerebrovascular 
disorder, stroke [220]. 
5. The classical RAS in stroke 
Blockade of the systemic RAS is routinely used for the treatment of 
hypertension through the use of ARBs and ACEis [18] and therefore this 
allows for the analysis of the effect of these systemic drugs on stroke 
outcome by acute BP modulation or risk through long-term BP control. 
In the LIFE trial, treatment for hypertension with the ARB losartan re-
sulted in 25% fewer strokes than with the β1 receptor antagonist (β- 
blocker) atenolol despite similar BP reductions [228], while the MOSES 
trial demonstrated fewer cerebrovascular and cardiovascular events 
over a 2.5 year follow-up period when patients who had suffered a 
stroke in the past two years were treated with the ARB eprosartan 
compared to the calcium channel blocker nitrendipine, despite similar 
BP reductions with both drugs [229]. In a randomized controlled trial 
comparing treatment with the ARB candesartan immediately following 
stroke or delayed until seven days later (ACCESS trial) there was no 
significant difference in functional outcome at three months, however 
early ARB treatment did significantly reduce the number of cardio-
vascular events [230]. An observational study of French stroke cohorts 
demonstrated no benefit of on-going ACEi or ARB treatment on stroke 
outcomes at 3 months [231]. However, in contrast to those studied 
described above, these patients also received thrombolysis with rt-PA. A 
meta-analysis of 26 clinical trials indicated that ARBs and ACEis offer 
no BP independent risk reduction for stroke [232]. 
Despite these varied results in clinical trials, there remains sig-
nificant evidence that the brain RAS plays a role in ischaemic stroke 
pathophysiology and may offer potential as a therapeutic target. In 
experimental stroke models, intracerebroventricular infusion of an ARB 
resulted in beneficial outcomes of improved neurological score or de-
creased infarct size following transient middle cerebral artery occlusion 
(tMCAO), a commonly used model of ischaemia-reperfusion stroke in-
jury, but did not lower the systemic BP due to the low dose utilised 
[233,234]. The dose was chosen to allow any BP-independent effects of 
the ARB to be identified and to avoid worsening outcome through ag-
gressive BP lowering in the acute period after stroke [233,234]. Simi-
larly, with systemic administration of an ARB dose too low to exert a BP 
lowering effect, pre- or post-tMCAO, reduced infarct volumes and im-
proved functional outcomes were observed [235–238]. The ACEi, ra-
mipril, however, demonstrated no neuroprotective effects with systemic 
delivery prior to tMCAO [235]. Furthermore, vaccination with an anti- 
Ang II antibody demonstrated neuroprotective effects with reduced 
infarct volume following permanent occlusion of the middle cerebral 
artery (pMCAO), another commonly used stroke animal model [239]. 
Although the antibody did not appear to penetrate the brain tissue of 
control rats, it could penetrate the ischaemic lesion to block AT1R 
signalling in the brain, but did not affect BP [239]. Studies with 
transgenic mice have further corroborated the detrimental effect of 
AT1R signalling in ischaemic stroke. Mice over-expressing human renin 
and angiotensinogen genes displayed higher levels of Ang II in the 
circulation and the brain and, as a result, worse neurological deficit 
following pMCAO compared to wild-type which was prevented with 
prior ARB treatment [240]. Moreover, over-expression of angiotensi-
nogen resulted in a smaller area of salvageable brain tissue (penumbra) 
at one hour and larger infarct volume at 24 h following pMCAO, while 
knockout (KO) of the AT1R resulted in the opposite effect [241]. Al-
though BP was affected by the overexpression of angiotensinogen (in-
creased) or AT1R KO (decreased) which may have impacted the re-
sultant infarct, the authors further demonstrated beneficial effects of 
AT1R KO on cell death in an oxygen glucose deprivation in vitro model 
suggesting BP independent effects [241]. Together, these results in-
dicate a detrimental effect of AT1R signalling in the setting of ischaemic 
stroke through mechanisms including neuroinflammation, ROS gen-
eration, apoptosis and neurodegeneration, all of which are independent 
of BP yet clinically, systemic blockade of AT1R has not been shown to 
consistently improve stroke outcome or risk. Therefore, perhaps the 
counter-regulatory axis of the RAS provides an alternative therapeutic 
target and indeed, there is increasing evidence that activation of the 
counter-regulatory RAS receptors is beneficial for stroke outcome 
(Table 1 & Table 2). 
6. Mas receptor and stroke 
Experimental models have demonstrated that Mas receptor and 
ACE2 mRNA are upregulated in the brain during cerebral ischaemia 
and, as a result, brain and plasma levels of Ang-(1–7) are also increased, 
suggesting that the Mas receptor/ACE2/Ang-(1–7) axis plays a role in 
ischaemic injury [75]. Additionally, further studies indicated that 
neuronal-specific ACE2 overexpression reduces infarct volume and 
improves neurological score after pMCAO and this is mediated by the 
Mas receptor [242]. Although ACE2 overexpression did result in a re-
duction in BP, titrating the systemic pressure to a similar level to that of 
control mice with norepinephrine demonstrated that the beneficial ef-
fects were independent of BP [242]. Similarly, activation of ACE2 by 
systemic injections [243] or intracerebroventricular infusion [244] of 
the ACE2 activator, diminazene aceturate (DIZE), pre- or post-stroke 
resulted in beneficial effects without affecting BP or cerebral blood flow 
(CBF) but the effect was abolished with Mas receptor blockade [244]. 
Interestingly, these studies with ACE2 only utilised the Mas receptor 
blocker A779 and did not assess the effect of AT2R blockade despite 
knowledge that Ang-(1–9) is also produced by ACE2 [34]; although 
reports of Ang-(1–9) being an active peptide of the counter-regulatory 
RAS were only beginning to emerge around this time [47,245]. Use of 
the AT2R antagonist PD123,319 might indicate whether Ang-(1–9) is 
involved in any of the effects of ACE2 activation, although interpreting 
results might be challenging in this setting due to an ACE2 activator 
altering levels of many different angiotensin peptides. For example, 
Ang-(1–7) is also reported to utilise the AT2R [128] while PD123,319 is 
also known to block MrgD, the receptor for the alternative angiotensin 
peptide alamandine [48]. Coupled with the knowledge of hetero-
dimerization of different angiotensin receptors [51–53] interpretation 
of data following use of PD123,319 might be complex. 
Beneficial effects of delivery of Ang-(1–7), acting via Mas receptor 
and not AT2R, have also been demonstrated post-stroke in experimental 
models with both delivery prior to stroke induction [244,246–248] and 
after reperfusion [249,250] (Table 1). Time of delivery varied from 
48 h [246], 7 days [244,248] to 4 weeks [247] prior to stroke, and 
continued to the study endpoint, typically 24 h [246–248] out to 3 days 
[244]. In those studies using post-stroke administration, treatment 
began as early as 90 min after occlusion (to coincide with reperfusion) 
[249] or at 90 min, 4/24/48 h after stroke [250]. Moreover, beyond the 
setting of ischaemic stroke, Ang-(1–7) treatment also improved survival 
and reduced haemorrhages in the stroke prone spontaneously hy-
pertensive rat which is a model of spontaneous haemorrhagic stroke 
[251]. The non-peptide Mas receptor agonist, AVE 0991, has had less 
consistent results with improved outcome when delivered intranasally 
in a subarachnoid hemorrhage model attributed to reduced oxidative 
stress and reduced apoptosis [148] but no benefits observed with sys-
temic delivery after stroke in an ischaemic stroke model [252]. In the 
latter study, the authors attribute the failure to dosing or timing issues 
considering they observed neuroprotective effects in an in vitro glucose 
deprivation model [252] and previous studies have demonstrated its 
ability to cross the blood brain barrier due to its hydrophobic nature 
[253]. 
The mechanisms behind Mas receptor neuroprotection in ischaemia 
reperfusion has been attributed to increased levels of bradykinin or the 
bradykinin receptors [154], reduced levels of ROS [246]; mediation of 
anti-inflammatory effects for example by inhibition of NFκB resulting in 
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reduction of IL1β or TNFα [153,246,248]; improved BBB stability due 
to increased tight junction protein expression and reduced expression of 
MMP9 via TIMP1 [254]; reduced levels of iNOS [244]; and production 
of NO which, aside from vasodilatory effects, can also induce pro-an-
giogenic signalling [247] (Table 1). Although activation of eNOS re-
sulting in NO production is a downstream signalling pathway of Mas in 
the brain [255] that can have a beneficial effect on stroke outcome 
[247], activation of iNOS may be detrimental to stroke outcome [256] 
and Ang-(1–7)/Mas signalling has demonstrated a reduction in iNOS 
expression [244,248]. 
These studies suggest an encouraging potential for Mas agonism as a 
neuroprotective treatment following ischaemic stroke, however the 
majority of promising results were obtained with intracerebral delivery 
of Ang-(1–7) (Table 1) with just one study using a more translationally 
relevant approach through oral administration [250]. Furthermore, all 
studies used only male healthy rodent animal models (SD or Wistar rats 
or C57BL6/J mice) and so co-morbidity and sex were not considered. 
That said, several stroke models have been studied including permanent 
and transient MCAO using endothelin-1 (ET-1) or the intraluminal fi-
lament models. Therefore, collectively, these studies fall short of many 
of the STAIR criteria for stroke studies [11] and there is much further 
work required before targeting this receptor could become a reality as a 
treatment for stroke patients. 
7. AT2R and stroke 
The importance of AT2R signalling in cerebral ischaemia was de-
monstrated with AT2R KO mice which displayed larger infarct volumes, 
worsened neurological score and reduced CBF, following pMCAO, than 
wild-type (WT) mice [257]. AT2R KO did not affect BP in these mice 
and inhibition of AT1R was not sufficient to rescue the effects of AT2R 
KO but rather demonstrates that the beneficial effects of AT1R inhibi-
tion in stroke is, in part, due to indirect AT2R stimulation [257]. 
Transient ischaemia also resulted in larger infarcts in AT2R KO mice 
compared to WT suggesting an important role in protection of IR injury 
[193]. Furthermore, numerous studies have shown, via different 
methods, that AT2R is upregulated following both permanent or tran-
sient MCAO which further suggests an upregulation as an endogenous 
protective response to ischaemia [77,258,259]. 
Agonism of AT2R has also demonstrated promising results in ex-
perimental stroke models (Table 2). Initial proof of concept studies 
utilised intracerebroventricular delivery of the peptide agonist of AT2R, 
CGP42112. Delivery five days prior to tMCAO significantly reduced 
infarct volume and improved motor deficits coupled with increased 
AT2R expression, improved neuronal survival and reduced ROS pro-
duction in the infarct area, all of which were prevented by AT2R 
blockade [260]. More encouragingly, commencement of in-
tracerebroventricular delivery of CGP42112 after tMCAO resulted in 
similar beneficial effects on infarct volume, motor deficit and neuronal 
survival as before, and also reduced apoptosis in the infarct and peri- 
infarct regions and increased microglia activation which may be a 
protective mechanism to remove cellular debris [261]. In both studies, 
CGP42112 had no effect on the BP of the spontaneously hypertensive 
rats (SHR) utilised. Systemic administration of CGP42112 at the com-
mencement of reperfusion also had beneficial effects on infarct volume 
and functional outcome in a mouse stroke model suggesting the peptide 
does not need to be delivered directly to the brain to have an effect 
[192]. 
Most of the research on the benefit of AT2R agonism in stroke has 
been conducted using the non-peptide agonist, C21 (Table 2). Once 
daily intraperitoneal (IP) injections of C21 in the two weeks prior to 
pMCAO in WT mice and AT2R KO mice demonstrated that C21 reduced 
infarct volume in WT but not KO mice [262]. Further, C21 delivery only 
after pMCAO also improved neurological score and infarct volume out 
to seven days post-stroke, with improved CBF, reduced ROS, BBB per-
meability and proinflammatory cytokines three days after stroke [262]. 
These promising results were further corroborated in hypertensive rats, 
where continuous intracerebroventricular delivery of C21 five days 
prior to tMCAO, or as four bolus doses beginning 6 h after tMCAO, 
resulted in reduced infarct volume and improved neuronal survival 
which was prevented by AT2R blockade [263]. However only the pre- 
treatment arm and not the post-treatment arm also demonstrated im-
proved motor deficit at 24 h and increased microglial activation [263]. 
It was further demonstrated that C21, via AT2R, induced vasorelaxation 
of basilar arteries in ex vivo myography experiments [263]. This may 
translate to an in vivo protective mechanism to improve CBF, although 
there was no effect of C21 on the systemic BP of the SHR [263]. Fur-
thermore, both before and after stroke, a high proportion of BDNF 
positive cells were also positive for AT2R implying that AT2R signalling 
is involved in BDNF release [263]. Studies have since had conflicting 
results with regard to the effect of C21 on CBF with some demonstrating 
no effect [193,264] while others suggest improvement [194], but BDNF 
mRNA and protein levels have been shown to be increased with C21 
treatment post-stroke and this effect is absent with AT2R KO [193]. 
Further studies demonstrated that IP delivery of C21 after stroke in-
duction, whether permanent or transient, improved outcome after 
stroke including in co-morbid animals with hypertension or advanced 
age [193,195,265–268] (Table 2). Additionally, AT2R signalling with 
C21 has demonstrated further translational potential with promising 
results achieved with post-stroke oral delivery in female rats [269] or in 
a type 2 diabetes animal model [270], or with an intranasal delivery 
approach resulting in high levels detectable in the cortex and striatum, 
and improved outcome following stroke [271]. 
Mechanisms behind the beneficial effects observed with C21 induced 
AT2R signalling in experimental stroke have been attributed to reduced 
proinflammatory cytokines [262,264], reduced apoptosis [193,265,267], 
reduced ROS and oxidative stress [194,262,267], increased VEGF produc-
tion [266], increased BDNF production [193,267], a switch from the M1 to 
M2 microglia phenotype [270], BBB stabilisation [194,262], and increased 
angiogenesis [267] (Table 2). Some of these effects have been demonstrated 
to be dependent on IL-10 [195] or peroxisome proliferator-activated re-
ceptor-gamma (PPARγ) activation [194] (Table 2). 
In addition, C21 AT2R signalling has also demonstrated reduced 
haemorrhagic transformation [267] and decreased β-amyloid (Aβ) de-
position following stroke [265,272]. Indeed, Aβ deposition is im-
plicated in cognitive impairment and C21 treatment has demonstrated 
beneficial effects on post-stroke cognitive impairment (PSCI) in both 
hypertensive [265] and aged rats [272], and in an embolic model of 
stroke [273]. Although results were promising in the embolic model, 
only C21 alone induced sensorimotor and cognitive improvements but 
not tPA alone or in combination with C21, suggesting translatability 
issues with the model considering tPA is the only clinically approved 
drug for stroke treatment [273]. Interestingly however, a recent clinical 
trial for the potentially neuroprotective compound NA-1 had similar 
results where benefits were seen only in patients who did not receive 
tPA [274]. This raises the possible potential for the use of drugs that 
offer benefits in the absence of tPA as a new treatment option for those 
patients who are ineligible for tPA treatment. 
Further to the benefits to PSCI mentioned above, AT2R agonism 
with C21 has also demonstrated beneficial effects on cognition in ani-
mals models utilising chronic hypoperfusion [275–277], Aβ injections 
in the brain (AD model) [278] or in a type 2 diabetes model [279]. C21 
produced increased CBF [276,278,279], reduced proinflammatory cy-
tokines [276], increased levels of BDNF in the brain [279] and reduced 
Aβ deposition [277] in these models and although no effect on overall 
vascular remodelling was observed, one study did demonstrate in-
creased size of the basilar artery which could be responsible for in-
creased blood supply to the hippocampus [275]. Furthermore, combi-
nation of C21 with memantine, an NMDA antagonist, and therefore 
glutamate toxicity modulator, used in AD, resulted in even greater le-
vels of BDNF in the brain but no additive effect on CBF or cognition was 
observed [279]. 
A. McFall, et al.   Cellular Signalling 76 (2020) 109809
10
Interestingly, although the brain RAS plays an important role in 
regulation of systemic BP and AT2R signalling can oppose vasocon-
strictive AT1R signalling, AT2R agonism by CGP4112 or C21 does not 
affect BP when the agonist is delivered before [262] or after [261,267] 
MCAO either by systemic [264], intracerebral [260] or intranasal [271] 
delivery nor after embolic stroke [273]. However, contrasting studies 
have been reported a marked hypotensive response following central 
C21 administration into conscious normo- [280,281] or hypertensive 
[281] rats. Therefore, given the uncertainty surrounding BP lowering in 
acute ischaemic stroke care, the lack of BP effect by AT2R agonism in 
stroke is encouraging and reassuring but should be considered cau-
tiously. 
Clearly there is strong evidence to support the role of protective 
effects of AT2R signalling in the brain and the potential of targeting this 
receptor as a treatment for ischaemic stroke and possibly PSCI. 
Collectively, these studies demonstrate consideration of many of the 
STAIR guidelines criteria for preclinical stroke studies [11] arguably 
placing this potential novel therapeutic, C21, ahead of other strategies 
to target the counter regulatory axis of the RAS in the setting of stroke. 
Furthermore, recently C21 was shown to be safe and well-tolerated 
when administered orally in healthy adult male volunteers [282] and 
further ongoing trials with C21 in Raynaud's phenomenon 
(ClinicalTrials.gov Identifier: NCT04388176), idiopathic pulmonary 
fibrosis (ClinicalTrials.gov Identifier: NCT04533022) and COVID-19 
(ClinicalTrials.gov Identifier: NCT04452435) will provide further evi-
dence on its safety in human subjects. 
8. Conclusion 
Cellular signalling via the Mas receptor and AT2R of the counter 
regulatory axis of the RAS has been well established and provides 
multiple mechanisms to oppose negative signalling effects of the AT1R 
within the cardiovascular system. Additionally, many of these signal-
ling mechanisms have been confirmed within the brain and could po-
tentially aid neuroprotection and brain repair following stroke. Indeed, 
preclinical stroke studies utilising agonism of the counter regulatory 
axis of the RAS demonstrate consistently encouraging results across 
several experimental and animal models, although often the cellular 
signalling mechanism mediating the beneficial effect is not confirmed. 
Encouragingly, many of these studies have used dosing protocols which 
would align with the window of therapeutic intervention afforded 
through existing stroke treatments, tPA or intra-arterial thrombectomy. 
Further well designed preclinical studies, for example utilising mixed 
sex cohorts with co- or multi-morbidities and considering the poly-
pharmacy associated with stroke patients may see progress in the tar-
geting of the brain counter regulatory RAS axis in stroke patients. 
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